| RRC ID |
61024
|
| 著者 |
Wang Y, Liu Y, Zhou C, Wang C, Zhang N, Cao D, Li Q, Wang Z.
|
| タイトル |
An AKR1C3-specific prodrug with potent anti-tumor activities against T-ALL.
|
| ジャーナル |
Leuk Lymphoma
|
| Abstract |
AKR1C3 overexpression has been reported in various types of cancers, including T-ALL. AST-006 (TH-3424), an AKR1C3-specific prodrug, was reported recently to have potent cytotoxicity against liver cancer cells overexpressing AKR1C3 and T-ALL. In this study, AST-006 demonstrated potent anti-tumor activity against different T-ALL cell lines in vitro and in vivo, including patient-derived xenograft (PDX) model. AST-006 also exhibited minimal cytotoxicity against primary human T-cells in vitro and lymphocytes in cynomolgus monkeys in vivo, indicating that AST-006 is a promising therapeutic for T-ALL.
|
| 巻・号 |
61(7)
|
| ページ |
1660-1668
|
| 公開日 |
2020-7-1
|
| DOI |
10.1080/10428194.2020.1728746
|
| PMID |
32091283
|
| MeSH |
Aldo-Keto Reductase Family 1 Member C3
Antineoplastic Agents, Alkylating
Cell Line, Tumor
Humans
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma*
Prodrugs* / pharmacology
Xenograft Model Antitumor Assays
|
| IF |
2.969
|
| リソース情報 |
| ヒト・動物細胞 |
ATN-1(RCB1440) |
